Have you heard of magic mushroom stocks? Pot stocks gave investors excellent returns in 2020. However, most investors did miss out on this opportunity. For the most part, magic mushrooms are largely illegal in the US, and research has shown the drug’s effectiveness could help treat conditions like depression, anxiety, and opioid addiction.
As of late, this industry has been demonstrating its potential. Therefore, it might not be a bad idea to look into the investment world of psychedelics. Many analysts consider this sector speculative and overpriced.
Best Magic Mushroom Stocks 2026
| Symbol | Name |
|---|---|
| TWGL | 20/20 Global |
| HAVLF | Havn Life Sciences |
| MCURF | Mind Cure Health Inc. |
| MNMD | Mindmed |
| MYCOF | Mydecine |
| NUMI | Numinous Wellness |
| CMPS | Compass Pathways |
| ATAI | Atai Life Sciences |
| CBYN | Cybin Inc. |
| GHRS | GH Research |
| ENVB | Enveric Biosciences |
| SEEL | Seelos Therapeutics |
Magic Mushroom Stocks Breakdown
Quite a few companies have also gained early popularity, like MindMed, because of who is backing them. With this information in light, let’s look at some Psychedelic stocks that have the potential to go up significantly in value. So, while you can’t trade magic mushroom stocks, you have options.
There are psychedelics you can trade. And there have been studies that something like magic mushrooms can help with medical and mental issues. This, of course, would be done with professionals and not something you get off the street.
Mind Medicine (NASDAQ: MNMD)
MindMed (NASDAQ: MNMD) is a company that offers a highly diverse range of psychedelic drugs in clinical development and also in R&D. Digital therapeutics are evidence-based therapeutic interventions for patients that help them manage, prevent, or treat a mental disorder or disease.
Mind Med is a good company because of its development projects, and it already has a pipeline of early-stage trials underway. Therefore, they cannot be patented because they were of natural origin or were found long ago by someone else.
Mind Medicine is one of the more advanced companies, but it is severely undervalued in its projects and big-name collaborators. This makes it a good investment because the future growth potential of this medicine is very bright.
Mydecine (OTC: MYCOF Stock Report) (CSE: MYCO)
Mushrooms are being used for their compounds, extracted and refined by Mydecine (MYCOF) and made available for purchase by other licensed companies. Mydecine is also planning to study the compounds for potential use down the line in psilocybin-assisted psychotherapy for PTSD.
Mind Cure Health Inc. (OTC: MCURF)
MCUR is one of the lesser-discussed magic mushroom stocks. The company has recently announced its psychedelic research program, and the initial focus will be on psilocybin, ketamine, and ibogaine. The company aims to provide its patients with treatments with ketamine and psilocybin.
20/20 Global (OTC Pink: TWGL)
The company is relatively new to the psychedelic world. Ehave is another psychedelic company in digital therapeutics and is developing a ketamine delivery platform that goes by the name of KetaDASH.
They’ve sold 100% of their Mycotia therapies subsidiary to 20/20 Global while acquiring 75% of Global’s outstanding shares. 20/20 Global will look into other business opportunities, including psychedelic retreats and medicinal mushrooms.
Havn Life Sciences (CSE: HAVLF)
Havn Life Sciences has gained a lot of investor attention and popularity because of the big names it owns. If you talk about the popular names in cannabis, Aphira is likely to be in the top five.
Havn Life Sciences has also announced a new partnership with the veterans’ mental health non-profit Westwood Institute. This partnership is strategic and aims to work on developing therapy using psychedelics for veterans.
Havn has also recently signed an MOU helping supply products and compounds for use in Heroic Heart’s future clinical studies. The company aims to research and investigate the effect of low-dose psychedelic compounds on veterans suffering from emotional trauma and PTSD.
Numinous Wellness (TSX: NUMI)
Numinous Wellness is a company that the Canadian government has recently licensed to cultivate, extract, and sell naturally sourced, sustainable psilocybin, also known as magic mushrooms. They’re also the owner of a dealer’s license.
This means that the company can import, export, test, and distribute MDMA, psilocybin, psilocin, DMT, and mescaline. Numinus Wellness has a great business plan and has a couple of credible advisors on board.
PSIL ETF Performance (2026 YTD)
| Year | Performance | 2026 (YTD) | -12.6% |
|---|---|
| 2025 | +9.8% |
| 2024 | -28.4% |
| 2023 | -18.7% |
| 2022 | -61.5% |
Final Thoughts: Magic Mushroom Stocks
The magic mushroom stocks industry could be good in the future. The competition between the dozens of biopharmaceutical companies is fierce. Many companies are seeking capital through which they can conduct expensive and lengthy drug trials, develop intellectual property, and help advance the treatment of various mental disorders. Whether you’re day trading or investing, these stocks could be options for you.
